Interdisciplinary approach to advanced ovarian cancer.
D000477:Alkylating Agents / Q000627:therapeutic use; D001201:Ascites / Q000150:complications / Q000532:radiotherapy; D002699:Chlorambucil / Q000627:therapeutic use; D003609:Dactinomycin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D007412:Intestinal Fistula / Q000150:complications; D007415:Intestinal Obstruction / Q000150:complications; D008525:Medroxyprogesterone / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D010051:Ovarian Neoplasms / Q000150:complications / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D010348:Patient Care Team; D010761:Phosphorus Radioisotopes; D011374:Progesterone / Q000627:therapeutic use; D011879:Radiotherapy Dosage; D013852:Thiotepa / Q000627:therapeutic use; D014228:Triaziquone / Q000627:therapeutic use; D014747:Vinblastine / Q000627:therapeutic use
D000477:Alkylating Agents; D010761:Phosphorus Radioisotopes; D002699:Chlorambucil; D003609:Dactinomycin; D011374:Progesterone; D014747:Vinblastine; D013852:Thiotepa; D014228:Triaziquone; D008525:Medroxyprogesterone; D005472:Fluorouracil; D008727:Methotrexate